• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

致编辑的信:对陈等人的回复

Letter to the editor: Reply to Chen et al.

作者信息

Heemsbergen Wilma D, de Vries Kim C, Incrocci Luca

机构信息

Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

Clin Transl Radiat Oncol. 2025 May 9;53:100979. doi: 10.1016/j.ctro.2025.100979. eCollection 2025 Jul.

DOI:10.1016/j.ctro.2025.100979
PMID:40476149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12140047/
Abstract

We have read the Letter to the Editor of Chen et al. with great interest, and appreciate their pursuit to expand the discussion on how patient-reported outcomes can inform toxicity risk stratification and supportive care strategies in real-world settings. We have added our vision to their raised points in order to contribute to this useful discussion.

摘要

我们饶有兴趣地阅读了陈等人致编辑的信,并赞赏他们致力于拓展关于患者报告结果如何为现实环境中的毒性风险分层和支持性护理策略提供信息的讨论。为了推动这一有益的讨论,我们已就他们提出的要点补充了我们的观点。

相似文献

1
Letter to the editor: Reply to Chen et al.致编辑的信:对陈等人的回复
Clin Transl Radiat Oncol. 2025 May 9;53:100979. doi: 10.1016/j.ctro.2025.100979. eCollection 2025 Jul.
2
Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.给编辑的信:《ICD-11 与 DSM-5 心境障碍分类的趋同与分歧》
Turk Psikiyatri Derg. 2021;32(4):293-295. doi: 10.5080/u26899.
3
Letter to the Editor: THE IMPACT OF THE COVID-19 PANDEMIC ON SCHIZOPHRENIA PATIENTS.致编辑的信:COVID-19 大流行对精神分裂症患者的影响。
Turk Psikiyatri Derg. 2021 Fall;32(3):219-221. doi: 10.5080/u26175.
4
Authors' Reply to Letter to the Editor by Chen et al.
J Natl Compr Canc Netw. 2021 Jan 6;19(1):xxxvb-xxxvib. doi: 10.6004/jnccn.2020.7671.
5
In reply to the Letter to the Editor by Chen and Lui regarding "Radiotherapy enhances uptake and efficacy of Y-cetuximab: A preclinical trial" by A Dietrich et al.针对陈和刘致编辑的信,信的内容是关于A·迪特里希等人的“放射治疗增强Y-西妥昔单抗的摄取和疗效:一项临床前试验”。
Radiother Oncol. 2021 Aug;161:261-262. doi: 10.1016/j.radonc.2021.06.014. Epub 2021 Jun 11.
6
Response to letter to the editor: Letter by Chen et al. regarding article, "Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study".对编辑来信的回复:陈等人就题为《评估钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)及其他抗糖尿病药物在阿尔茨海默病中的作用:一项基于人群的研究》的文章所写的信。
Pharmacol Res. 2025 May;215:107701. doi: 10.1016/j.phrs.2025.107701. Epub 2025 Mar 19.
7
Letter to the Editor in response to Chen et al. 2020.致编辑的信,回应陈等人 2020 年的文章。
Respir Res. 2020 Nov 30;21(1):315. doi: 10.1186/s12931-020-01548-0.
8
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger's Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468-75.对费利克斯·梅尔基奥尔、安德烈亚斯·皮尔彻和伊莎贝尔·海德格尔致编辑信的回复:关于约翰·S·德博诺、孟河、陈石等人。3期IPATential150试验中接受伊帕萨替布和阿比特龙治疗的患者的最终总生存期及与临床结局相关的分子数据。《欧洲泌尿外科杂志》。2025年;87卷:468 - 475页。
Eur Urol. 2025 Jun;87(6):e115-e116. doi: 10.1016/j.eururo.2025.03.020. Epub 2025 Apr 10.
9
Reply to Ugo Giovanni Falagario, Alberto Martini, Francesco Pellegrino, et al.'s Letter to the Editor re: Derya Tilki, Ming-Hui Chen, Jing Wu, et al. Prostate-specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol 2023;41:2428-35.
Eur Urol Oncol. 2024 Feb;7(1):166. doi: 10.1016/j.euo.2023.05.009. Epub 2023 Jun 12.
10
Reply to "Letter to the Editor Re: Scott S.N., et al. Nutrients 2019, 11(5), 1022".回复“致编辑的信:Scott S.N.等人,营养素 2019, 11(5), 1022”。
Nutrients. 2019 Nov 7;11(11):2699. doi: 10.3390/nu11112699.

本文引用的文献

1
Refining the interpretation of post-radiotherapy urinary and bowel outcomes in prostate cancer: A clinical perspective.优化前列腺癌放疗后泌尿和肠道结局的解读:临床视角
Clin Transl Radiat Oncol. 2025 May 3;53:100973. doi: 10.1016/j.ctro.2025.100973. eCollection 2025 Jul.
2
Post-treatment changes in bowel and urinary function in prostate cancer patients treated with moderate or ultra-hypofractionation: A prospective cohort study.中度或超分割放疗的前列腺癌患者治疗后肠道和泌尿功能的变化:一项前瞻性队列研究。
Clin Transl Radiat Oncol. 2025 Apr 7;53:100955. doi: 10.1016/j.ctro.2025.100955. eCollection 2025 Jul.
3
Handling missing values in patient-reported outcome data in the presence of intercurrent events.在存在并发事件的情况下处理患者报告结局数据中的缺失值。
BMC Med Res Methodol. 2025 Mar 1;25(1):56. doi: 10.1186/s12874-025-02510-8.
4
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.单臂研究中涉及肿瘤患者报告结局数据:当前实践的文献综述。
Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9.
5
Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer.局部前列腺癌男性患者的治疗方式、功能结局和基线特征与治疗相关遗憾的关系。
JAMA Oncol. 2022 Jan 1;8(1):50-59. doi: 10.1001/jamaoncol.2021.5160.
6
The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer.前列腺癌男性患者中,排尿和性功能与困扰对健康效用的相对影响。
JNCI Cancer Spectr. 2020 May 25;4(5):pkaa044. doi: 10.1093/jncics/pkaa044. eCollection 2020 Oct.